Design Therapeutics posts 2026 shareholder vote results
Design Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Design Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders. As of the April 14, 2026 record date, 62,441,429 shares of common stock were outstanding and entitled to vote.
Stockholders elected Simeon George, M.D. as a Class II director, with 29,205,208 votes for, 7,608,724 votes withheld and 13,264,883 broker non-votes. They also ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 50,077,708 votes for, 201 votes against and 906 abstentions.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Shares entitled to vote: 62,441,429 shares
Votes for director: 29,205,208 votes
Votes withheld director: 7,608,724 votes
+4 more
7 metrics
Shares entitled to vote
62,441,429 shares
Common stock outstanding as of April 14, 2026 record date
Votes for director
29,205,208 votes
Votes for Simeon George, M.D. as Class II director
Votes withheld director
7,608,724 votes
Votes withheld for Simeon George, M.D. election
Broker non-votes director
13,264,883 votes
Broker non-votes on director election proposal
Votes for auditor
50,077,708 votes
For ratification of Ernst & Young LLP as auditor for 2026
Votes against auditor
201 votes
Against ratification of Ernst & Young LLP
Abstentions auditor
906 votes
Abstentions on auditor ratification proposal
Key Terms
Emerging growth company, Annual Meeting of Stockholders, broker non-votes, independent registered public accounting firm, +1 more
5 terms
Emerging growth company regulatory
"Emerging growth company On June 9, 2026, Design Therapeutics, Inc."
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Annual Meeting of Stockholders financial
"held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”)."
broker non-votes financial
"Votes For | | Votes Withheld | | Broker Non-Votes Simeon George, M.D."
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm financial
"as the Company’s independent registered public accounting firm for the fiscal year"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
Audit Committee financial
"ratified the selection by the Audit Committee of the Company’s Board of Directors"
A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Design Therapeutics (DSGN) report from its 2026 Annual Meeting?
Design Therapeutics reported final voting results from its 2026 Annual Meeting. Stockholders elected one Class II director and ratified the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, detailing vote counts for each proposal.
Was Simeon George, M.D. elected to the Design Therapeutics board in 2026?
Yes, stockholders elected Simeon George, M.D. as a Class II director. He received 29,205,208 votes for and 7,608,724 votes withheld, with 13,264,883 broker non-votes, and will serve until the 2029 Annual Meeting or until a successor is duly elected.
Who is Design Therapeutics’ independent auditor for fiscal year 2026?
Stockholders ratified Ernst & Young LLP as Design Therapeutics’ independent registered public accounting firm for the year ending December 31, 2026. The ratification received 50,077,708 votes for, 201 votes against and 906 abstentions, with broker non-votes reported as not applicable.
What were the broker non-votes on Design Therapeutics’ director election?
The director election for Simeon George, M.D. recorded 13,264,883 broker non-votes. Broker non-votes arise when brokers lack discretionary authority to vote uninstructed shares on certain proposals, which can affect quorum and approval thresholds but do not count as votes for or against.
Did Design Therapeutics face any significant opposition to its 2026 auditor ratification?
Opposition to the 2026 auditor ratification was minimal. Ernst & Young LLP received 50,077,708 votes for, only 201 votes against and 906 abstentions. Broker non-votes were not applicable to this proposal, indicating broad shareholder support for the selected audit firm.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates